SMT202400427T1 - Nuovo uso dell'agonista del recettore dell'angiotensina ii di tipo 2 - Google Patents
Nuovo uso dell'agonista del recettore dell'angiotensina ii di tipo 2Info
- Publication number
- SMT202400427T1 SMT202400427T1 SM20240427T SMT202400427T SMT202400427T1 SM T202400427 T1 SMT202400427 T1 SM T202400427T1 SM 20240427 T SM20240427 T SM 20240427T SM T202400427 T SMT202400427 T SM T202400427T SM T202400427 T1 SMT202400427 T1 SM T202400427T1
- Authority
- SM
- San Marino
- Prior art keywords
- angiotensin
- type
- receptor agonist
- new use
- new
- Prior art date
Links
- 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 title 1
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004209.9A GB202004209D0 (en) | 2020-03-23 | 2020-03-23 | New use |
| GBGB2009574.1A GB202009574D0 (en) | 2020-06-23 | 2020-06-23 | New use |
| US17/113,416 US11123329B1 (en) | 2020-03-23 | 2020-12-07 | Use of angiotensin II type 2 receptor agonist |
| EP21715306.3A EP4125881B1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
| PCT/GB2021/050699 WO2021191592A1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202400427T1 true SMT202400427T1 (it) | 2024-11-15 |
Family
ID=77747178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20240427T SMT202400427T1 (it) | 2020-03-23 | 2021-03-22 | Nuovo uso dell'agonista del recettore dell'angiotensina ii di tipo 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123329B1 (https=) |
| EP (1) | EP4125881B1 (https=) |
| JP (1) | JP7671305B2 (https=) |
| CN (1) | CN115605201A (https=) |
| CA (1) | CA3176108A1 (https=) |
| ES (1) | ES2992423T3 (https=) |
| HR (1) | HRP20241435T1 (https=) |
| HU (1) | HUE068662T2 (https=) |
| PL (1) | PL4125881T3 (https=) |
| RS (1) | RS66072B1 (https=) |
| SM (1) | SMT202400427T1 (https=) |
| WO (1) | WO2021191592A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| US20220233480A1 (en) * | 2020-03-23 | 2022-07-28 | Vicore Pharma Ab | Use of angiotensin ii type 2 receptor agonist |
| AU2021258178A1 (en) * | 2020-04-22 | 2022-11-17 | Airway Therapeutics, Inc. | Use of surfactant protein D to treat viral infections |
| US20240408065A1 (en) * | 2021-09-30 | 2024-12-12 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Cyano compound, and preparation method therefor and use thereof |
| CN115583984A (zh) * | 2022-01-11 | 2023-01-10 | 嘉兴安谛康生物科技有限公司 | 氮杂螺类化合物及其制备方法、药物组合物和用途 |
| CN114948950A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种药物组合物及其抗病毒用途 |
| WO2024153020A1 (zh) * | 2023-01-16 | 2024-07-25 | 海南先声药业有限公司 | 抗病毒药物组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1529697B (zh) | 2001-05-31 | 2010-09-22 | 维科尔药物公司 | 用作血管紧张素ⅱ激动剂的三环化合物 |
| EP1723962A1 (en) | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| EP3265082A1 (en) | 2015-03-02 | 2018-01-10 | Vicore Pharma AB | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
-
2020
- 2020-12-07 US US17/113,416 patent/US11123329B1/en active Active
-
2021
- 2021-03-22 EP EP21715306.3A patent/EP4125881B1/en active Active
- 2021-03-22 WO PCT/GB2021/050699 patent/WO2021191592A1/en not_active Ceased
- 2021-03-22 CA CA3176108A patent/CA3176108A1/en active Pending
- 2021-03-22 SM SM20240427T patent/SMT202400427T1/it unknown
- 2021-03-22 RS RS20241153A patent/RS66072B1/sr unknown
- 2021-03-22 PL PL21715306.3T patent/PL4125881T3/pl unknown
- 2021-03-22 HR HRP20241435TT patent/HRP20241435T1/hr unknown
- 2021-03-22 ES ES21715306T patent/ES2992423T3/es active Active
- 2021-03-22 JP JP2022557150A patent/JP7671305B2/ja active Active
- 2021-03-22 HU HUE21715306A patent/HUE068662T2/hu unknown
- 2021-03-22 CN CN202180035480.3A patent/CN115605201A/zh active Pending
- 2021-08-27 US US17/458,886 patent/US20210386712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992423T3 (es) | 2024-12-12 |
| JP7671305B2 (ja) | 2025-05-01 |
| US11123329B1 (en) | 2021-09-21 |
| CN115605201A (zh) | 2023-01-13 |
| EP4125881A1 (en) | 2023-02-08 |
| JP2023520323A (ja) | 2023-05-17 |
| US20210386712A1 (en) | 2021-12-16 |
| EP4125881C0 (en) | 2024-07-24 |
| RS66072B1 (sr) | 2024-11-29 |
| CA3176108A1 (en) | 2021-09-30 |
| HUE068662T2 (hu) | 2025-01-28 |
| PL4125881T3 (pl) | 2024-12-02 |
| US20210290596A1 (en) | 2021-09-23 |
| HRP20241435T1 (hr) | 2024-12-20 |
| WO2021191592A1 (en) | 2021-09-30 |
| EP4125881B1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE068662T2 (hu) | Angiotenzin-ii-receptor-2 agonista új alkalmazása | |
| SI4212527T1 (sl) | Agonistična spojina receptorja GLP-1R in njena uporaba | |
| IL324507A (en) | Thr-beta receptor agonist compound and method for its preparation and use | |
| PL3989972T3 (pl) | Agoniści receptora glukagonopodobnego peptydu 1 | |
| HUE070634T2 (hu) | GLP-1 receptor agonista | |
| IL277044A (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| ZA202102263B (en) | Oral formulations of kappa opioid receptor agonists | |
| GB2603330B (en) | Heterocyclic THR-B receptor agonist compound and preparation method and use therefor | |
| MA31563B1 (fr) | Combinaisons synergiques d'antagonistes vr-1 et d'inhibiteurs de cox-2 | |
| IL304329A (en) | Use of a melanocortin-4 receptor agonist | |
| ZA201908471B (en) | New uses of a pure 5-ht 6 receptor antagonist | |
| ZA202006157B (en) | Pharmaceutical composition of kor receptor agonist | |
| EP3952852A4 (en) | PROPHYLACTIC EFFECTIVENESS OF SEROTONIN-4 RECEPTOR AGONISTS AGAINST STRESS | |
| EP3549948A4 (en) | AGONISTIC PEPTIDE FOR ADIPONECTIN RECEPTOR | |
| IL291502A (en) | agonist for tacr2 | |
| EP4091623A4 (en) | CALCIUM SENSING RECEPTOR AGONIST COMPOUND AND ITS APPLICATION | |
| EP3851106A4 (en) | MEDICAL USES OF PROSTACYCLIN RECEPTORAGONISTS | |
| IL315279A (en) | Selective G protein-coupled receptor kinase 5 inhibitors, compositions and methods of use | |
| AU2021349680A9 (en) | Use of sphingosine-1-phosphate receptor agonist | |
| IL326685A (en) | Kappa opioid receptor antagonists | |
| GB202108483D0 (en) | Modulator of g protein-coupled receptor 88 | |
| HK40076468A (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |